Our Innovative Projects
PDX/O Oncology Platform
InnoSer has many collaborative projects with research groups from both academia and industry settings to develop novel technologies for use in preclinical settings. This includes a project executed in partnership with Vrije Universiteit Brussel and in close collaboration with Jessa Hospital in Hasselt, Belgium, and Leiden University Medical Center (LUMC, the Netherlands) that resulted in the development of an integrated PDXO drug screening platform. This platform consists of two complementary components, patient-derived xenografts (PDX) and patient-derived organoids (PDO), which are characterized in the same manner. Such models resemble the original patient-derived tumour both phenotypically and genetically. For this reason, one of the main advantages of such a platform is its predictive value in drug screening, as your compounds can be coherently tested both in vitro and in vivo, using the same starting parental material.
Many xenografts, organoids or combined models are already validated and currently available for compound testing. For other models, we are happy to collaborate and validate the platform with your compounds.
Want to read more?
Knocking out Pkd1 in the P40 mouse model enables extended dosing windows and long-term efficacy studies
It is well-established that ADPKD shows heterogeneous disease onset and progression in patients, necessitating preclinical models that capture the heterogeneous disease penetration observed in patients. Therefore, new datasets in our adult-onset (also referred to as...
![Proven Compound Susceptible Tau[P301S] Mouse Model for Preclinical Proof of Concept](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/Proven-Compound-susceptible-TauP301S-mouse-model-for-preclinical-proof-of-concept--400x250.png)
Proven Compound Susceptible Tau[P301S] Mouse Model for Preclinical Proof of Concept
The Tau[P301S] mouse remains one of the most established in vivo models for evaluating therapeutics targeting tauopathies including Alzheimer's disease and frontotemporal dementia (FTD). Presented at AD/PD 2025 in Vienna, this poster provides comprehensive...
InnoSer Presents New Data at the 8th CKD Summit 2026: Advancing Preclinical Models for ADPKD Research
Next week, the kidney research community will gather in Boston for the 8th CKD Summit 2026, a premier event that brings together clinicians, researchers, and industry experts to discuss the latest advances in chronic kidney disease (CKD) research and therapy...